Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Cardiff Oncology, Inc. | a15-14922_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 29, 2015
Trovagene, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-35558 |
|
27-2004382 |
|
(State or other jurisdiction |
|
(Commission File |
|
IRS Employer |
|
of incorporation or organization) |
|
Number) |
|
Identification No.) |
11055 Flintkote Avenue, Suite A
San Diego, CA 92121
(Address of principal executive offices)
Registrant’s telephone number, including area code: (858) 952-7570
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On June 29, 2015, Trovagene, Inc. (the “Company”) issued a press release announcing that the Company is now included in the Russell 3000® , the Russell 2000® Small Cap, and Russell Global® Indexes. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
|
99.1 |
Press Release of Trovagene, Inc. dated June 29, 2015 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 29, 2015
|
|
TROVAGENE, INC. | |
|
|
| |
|
|
| |
|
|
By: |
/s/ Antonius Schuh |
|
|
|
Antonius Schuh |
|
|
|
Chief Executive Officer |